The forecast for ovary malignant neoplasms mortality in the US shows a gradual decline from 2024 to 2028. Expressed in standardized rates per hundred thousand women, the mortality rate decreases from 6.6 in 2024 to 5.8 in 2028. Comparing year-over-year variations, there's an approximate annual reduction of 3% in mortality rates. From a longer-term perspective, the five-year period from 2024 exhibits a consistent downward trend with a compound annual growth rate (CAGR) of approximately -3.2%.
Future trends to watch for include advancements in early detection and treatment innovations which could further accelerate the decline in mortality rates. Additionally, ongoing public health initiatives aimed at raising awareness and improving access to healthcare may continue contributing to these reductions.
